

Sterling Biotech Limited
Registered Office : 43, Atlanta Building, Nariman Point, Mumbai - 400021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE SECOND QUARTER ENDED 30th JUNE, 2007

Rs. In Lacs

Sr. No.	Particulars	Quarter ended 30-06-2007 (Unaudited)	Corresponding Quarter ended 30-06-2006 (Unaudited)	Six Month ended 30-06-2007 (Unaudited)	Six Month ended 30-06-2006 (Unaudited)	For the year ended 31-12-2006 (Audited)
1	Net Sales	22,706.31	14,271.34	40,109.60	27,659.04	60,585.36
2	Other Income	247.65	94.73	479.68	176.61	504.52
3	Total Income	22,953.96	14,366.07	40,589.28	27,835.65	61,089.88
4	Total Expenditure	12,390.17	7,471.81	21,568.47	14,650.45	31,865.14
	a) (Increase)/Decrease in Stocks	(2,831.79)	(239.41)	(3,246.57)	(470.45)	(1,268.81)
	b) Consumption of raw materials	10,795.23	4,853.24	16,746.76	9,456.46	20,997.60
	c) Staff Cost	477.92	380.70	936.78	750.01	1,626.88
	d) Other Expenditure	3,948.81	2,477.28	7,131.50	4,914.43	10,509.47
5	Interest	965.86	1,030.95	2,019.37	2,059.11	4,116.70
6.	Gross Profit	9,597.93	5,863.31	17,001.44	11,126.09	25,108.04
7	Depreciation	2,018.21	1,422.89	3,933.94	2,656.95	6,202.55
8	Profit before Extraordinary Expenditure and Tax	7,579.72	4,440.42	13,067.50	8,469.14	18,905.49
9	Extraordinary Expenditure (Non Recurring)	320.11	161.29	481.40	322.58	645.14
10	Profit after Extraordinary Expenditure but before tax	7,259.61	4,279.13	12,586.10	8,146.56	18,260.35
11	Provision for Current Tax	800.00	550.00	1,365.00	870.00	1,900.00
12	Provision for Deferred Tax	1,625.00	660.00	2,575.00	1,175.00	2,850.00
13.	Provision for Fringe Benefit Tax	6.00	8.54	11.87	17.43	30.75
14	Net Profit	4,828.61	3,060.59	8,634.23	6,084.13	13,479.60
15	Prior Year Adjustment	0.00	0.00	0.00	0.00	128.99
16	Profit available for appropriation	4,828.61	3,060.59	8,634.23	6,084.13	13,350.61
17	Paid-up Equity Capital (Face Value Rs. 1/- per share)	2,259.05	2,212.49	2,259.05	2,212.49	2,223.48
18	Reserves Excluding Revaluation Reserves					99,048.80
19	Basic EPS (Not Annualised) on F.V. Rs.1/-	2.14	1.38	3.82	2.75	6.00
20	Diluted EPS (Not Annualised) on F.V. Rs.1/-	2.14	1.38	3.82	2.75	6.00
21	Aggregate of Public Shareholding					
	a) No. of Shares (F.V. of Re. 1/-)	147,931,886 65.48%	154,313,738 69.75%	147,931,886 65.48%	154,313,738 69.75%	152,125,969 68.42%
	b) Percentage of Shareholdings					

1. The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
2. The above financial results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 31st July, 2007.
3. The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30th June, 2007.
4. The number of investor complaints for the quarter ended 30th June, 2007 were :
Opening – 7, Received - 17, Disposed off - 17, and Balance - 7.

For and On Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 31st July, 2007

Nitin J. Sandesara
Chairman & Managing Director